Senti Biosciences (SNTI) Operating Income (2021 - 2025)
Senti Biosciences' quarterly Operating Income came in at -$18.6 million in Q4 2025, down 15.27% year-on-year from -$22.0 million in Q4 2024, and down 9.96% quarter-over-quarter from -$16.9 million in Q3 2025.
Senti Biosciences has reported Operating Income for 5 years, with the latest figure at -$18.6 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Income fell 15.27% year-over-year to -$18.6 million; the trailing twelve-month figure through Dec 2025 stood at -$68.8 million (down 12.68% YoY), and the FY2025 full-year result was -$68.8 million, down 12.68% from the prior year.
- Operating Income for Q4 2025 stood at -$18.6 million, down from -$16.9 million in the prior quarter.
- The five-year high for Operating Income was -$1178.0 in Q1 2021, with the low at -$43.9 million in Q3 2023.
- Average Operating Income over 5 years is -$15.6 million, with a median of -$15.7 million recorded in 2024.
- Year-over-year, Operating Income slumped 998032.43% in 2022 and jumped 65.32% in 2024.
- Tracing SNTI's Operating Income over 5 years: stood at -$3.9 million in 2021, then tumbled by 334.42% to -$16.8 million in 2022, then dropped by 11.34% to -$18.7 million in 2023, then climbed by 13.54% to -$16.2 million in 2024, then retreated by 15.27% to -$18.6 million in 2025.
- The last three Operating Income figures came in at -$18.6 million (Q4 2025), -$16.9 million (Q3 2025), and -$16.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.64 Mn |
| Sep 30, 2025 | -16.95 Mn |
| Jun 30, 2025 | -16.80 Mn |
| Mar 31, 2025 | -16.40 Mn |
| Dec 31, 2024 | -16.17 Mn |
| Sep 30, 2024 | -15.22 Mn |
| Jun 30, 2024 | -13.36 Mn |
| Mar 31, 2024 | -16.30 Mn |
| Dec 31, 2023 | -18.70 Mn |
| Sep 30, 2023 | -43.88 Mn |
| Jun 30, 2023 | -15.19 Mn |
| Mar 31, 2023 | -14.96 Mn |
| Dec 31, 2022 | -16.79 Mn |
| Sep 30, 2022 | -14.75 Mn |
| Jun 30, 2022 | -21.77 Mn |
| Mar 31, 2022 | -11.76 Mn |
| Dec 31, 2021 | -3.87 Mn |
| Sep 30, 2021 | -11.42 Mn |
| Jun 30, 2021 | -9.00 Mn |
| Mar 31, 2021 | -1,178.00 |